Related Experiment Video

Updated: May 21, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?

Jacopo Giuliani1, Fabrizio Drudi

  • 1Clinical Oncology Unit, St. Anna University Hospital , Ferrara, Italy. giuliani.jacopo@alice.it

Cancer Biotherapy & Radiopharmaceuticals
|June 29, 2012
PubMed
Abstract

Insights

In metastatic renal cell carcinoma (mRCC), targeted therapies in later lines of treatment showed a survival advantage over earlier use. Further trials are needed to define optimal sequencing and the role of immunotherapy.

Area of Science:

  • Oncology
  • Clinical Research

Background:

  • The optimal sequence of targeted therapy for metastatic renal cell carcinoma (mRCC) remains undefined.
  • Treatment decisions are often influenced by patient comorbidities and toxicity profiles.

Purpose of the Study:

  • To evaluate the clinical outcomes of targeted therapies in mRCC post-cytokine era.
  • To compare the effectiveness of different treatment sequences for mRCC.

Main Methods:

  • Retrospective analysis of 61 mRCC patients treated between June 1998 and September 2010.
  • Categorization of patients based on therapy: cytokine-only, first-line targeted therapy, or second/subsequent-line targeted therapy.

Main Results:

  • Targeted therapies in second or subsequent lines demonstrated a statistically significant advantage in overall survival (p=0.024).
  • Sunitinib was the primary first-line targeted therapy used in this cohort.

Conclusions:

  • Later-line targeted therapy appears more effective for overall survival in mRCC.
  • Re-evaluation of immunotherapy, potentially with bevacizumab, in first-line treatment warrants further investigation.
  • Larger clinical trials are necessary to establish definitive treatment guidelines for mRCC.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...